Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

155
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
155
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

114
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
114
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

209
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
209
Bipolar Disorder01:30

Bipolar Disorder

60
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
60
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

208
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
208
Drug Therapy01:28

Drug Therapy

41
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
41
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Pharmacology And Pharmaceutical Sciences
  9. Basic Pharmacology
  11. Expert Guidelines On The Use Of Cariprazine In Bipolar I Disorder: Consensus From Southeast Asia.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Pharmacology And Pharmaceutical Sciences
  9. Basic Pharmacology
  11. Expert Guidelines On The Use Of Cariprazine In Bipolar I Disorder: Consensus From Southeast Asia.

Related Experiment Video

Developing a Rat Model for Bipolar Disorder
04:44

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

225

Expert Guidelines on the Use of Cariprazine in Bipolar I Disorder: Consensus from Southeast Asia.

Ahmad Hatim Sulaiman1, Mustafa M Amin2, Jin Kiat Ang3

  • 1Department of Psychological Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia.

Healthcare (Basel, Switzerland)
|June 13, 2025

View abstract on PubMed

Summary
This summary is machine-generated.

Expert consensus recommends cariprazine as a safe and effective treatment for bipolar 1 disorder (BP1D). This guidance offers practical insights for using cariprazine in bipolar depression and mania management.

Keywords:
Southeast Asiabipolar I disorderbipolar depressionbipolar mania

More Related Videos

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

632
Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.0K

Related Experiment Videos

Developing a Rat Model for Bipolar Disorder
04:44

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

225
Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

632
Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.0K

Area of Science:

  • Psychiatry
  • Pharmacology

Background:

  • Cariprazine, a D3/D2 partial agonist, is a key treatment for bipolar 1 disorder (BP1D) in Southeast Asia.
  • Existing literature lacks comprehensive practical guidance on cariprazine use for BP1D.

Purpose of the Study:

  • To develop expert-driven consensus recommendations for the safe and effective use of cariprazine in BP1D.
  • To address practical aspects of cariprazine therapy not fully detailed in current literature.

Main Methods:

  • Modified RAND/UCLA Appropriateness Method utilized.
  • Expert panel (n=13) of psychiatrists from Southeast Asia.
  • Two rounds of rating clinical scenarios followed by face-to-face discussion.

Main Results:

  • Recommended trial durations: 4-8 weeks for bipolar depression, 3-4 weeks for acute mania/mixed.
cariprazine
mixed episode
  • Long-term treatment (>1 year) recommended by majority for both mania and depression.
  • Cariprazine deemed suitable as first-line therapy for first-episode depression and mania.

    • Conclusions:

    • Consensus recommendations provide practical guidance for clinicians managing adult BP1D patients.
    • Emphasizes informed decision-making considering individual patient circumstances.
    • Aims to optimize cariprazine's role in BP1D treatment.